News | June 26, 2007

Novel Bioresorbable Coronary Stent Begins Clinical Evaluation

June 27, 2007 — REVA Medical, Inc. recently announced enrollment of the first patients in a first-in-man clinical trial designed to evaluate the safety of the REVA Bioresorbable Coronary Stent for the treatment of coronary artery disease.

The RESORB (REVA Endovascular Study of a Bioresorbable Coronary Stent) trial will enroll up to 30 patients at multiple sites in Germany and Brazil in a non-randomized study with an initial assessment of major adverse cardiac events (MACE) at 30 days and a follow-up period of five years.

The REVA Stent is intended to act as a temporary scaffold to support the vessel during the healing process. Once the vessel has healed, the stent is designed to resorb, leaving the patient free of a permanent implant.

In preclinical studies, REVA’s unique stent geometry and proprietary polymer have demonstrated mechanical performance similar to metal stents and sustained biocompatibility.

In 2004, REVA established a strategic relationship with Boston Scientific Corporation a worldwide developer and marketer of interventional medical devices.

For more information:

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init